Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > The slow process to success, part 3

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Aug 07, 2021 3:08pm

191 Views

Post# 33668633

RE:RE:The slow process to success, part 3

Scotty wrote: You expect CLAS, aka KLY to have a its share price increase by 12.5 to 20.83 times in 2 ish months? Easily the craziest prediction I've ever heard of. Bitcoin would be jealous.

Best to save your skepticism until Nov or risk looking like you don't know what your are talking about. You can always come back and do he same in Nov. if this proves wrong.

<< Previous

Bullboard Posts

Next >>

Three mispriced stocks exposed to major market tailwinds